Ceres Ventures, a company that deals with development of clean technologies for purification of water, soil and air, has announced that the company’s subsidiary, BluFlow Technologies has devised a proprietary technique to commercialize production of BluFlow nanoparticles and is in the process of acquiring a patent for its BluFlow water treatment technology that already has four patent filings to its name.
As a precursor to impending field tests, the company will carry out a treatability study of its patent-pending BluFlow water treatment technology at contaminated groundwater sites identified by a US Professional Engineering & Consulting Firm that will be working in conjunction with the company on the study.
The principal focus of the study will be on the removal of two organic compounds from groundwater at the premises of one of the clients of the Engineering firm. One compound is deemed as a regulated contaminant as per the Safe Drinking Act of the United States Environmental Protection Agency. The second compound is considered to be a human carcinogen and figures in the 12th Report on Carcinogens from the U.S. Department of Health and Human Services. The compound is prevalent as a water contaminant throughout the United States.
In addition, the California Environmental Protection Agency suspects the compound to be a respiratory toxicant, neuro-toxicant and kidney toxicant. The BluFlow Treatment system offers integrated treatment that not only efficiently eliminates specific compounds or contaminants but also purifies 95% of remaining water by employing a unique recirculation system to minimize rejection of wastewater.